Origenis beruft Dr. Peter Seufer-Wasserthal zum Chief Business Officer

Martinsried, Germany, March 22, 2018 - Origenis GmbH, a German biotech company
specializing in the discovery and development of highly selective small molecule kinase
inhibitors for CNS disorders, today announced the appointment of Dr. Peter Seufer-
Wasserthal as Chief Business Officer.

Dr. Seufer-Wasserthal brings 25 years experience in technology oriented business
development to the company. Prior to joining Origenis, he served as Vice President Business
Development at Intrexon Corporation (NYSE: XON) and before that held several senior
executive and business development positions at Codexis, Inc., (NASDAQ: CDXS), where
he closed numerous licensing, research and supply agreements. Before Codexis, Dr. Seufer-
Wasserthal managed a broad range of drug discovery collaborations, licensed pre-clinical
candidates to Pharma partners and directed several drug development projects in the
position of Senior Vice President of Business Development at Morphochem and Evotec. He
holds a Ph.D. in organic chemistry from the Technical University of Graz.

Origenis´CEO Michael Almstetter welcomed Dr. Seufer-Wasserthal: “We are excited to have
Peter join at this stage of our growth. Beyond our focus on highly selective small molecule
kinase inhibitors for CNS disorders, Origenis has developed a comprehensive set of non-
CNS and ophthalmological assets that are validated by several Pharma partnerships and
have the potential to significantly contribute to the company's top line. Peter will lead Origenis´
business activities and grow our relationships in the pharmaceutical market to establish
additional collaborations with leading companies in the field. I am confident that his deep
industry insight and proven closing capabilities will be a tremendous asset to Origenis.”-ends-

Download press release